Evidence map›Paper›PMID 33417257›Full record

ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2021

Mechanisms of oral immunotherapy.

Suzanne M Barshow, Michael D Kulis, A Wesley Burks, Edwin H Kim

Open access · greenAbstract readReview
In one paragraph

Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Diverging in Vivo Immune Response Patterns After Oral Food Challenge in Peanut Allergic Adults.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  5. Article
  6. Article
  7. Irradiation does not impact the immunogenicity of food flours used for oral immunotherapy.The journal of allergy and clinical immunology. Global · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Eating away at food allergy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  16. Article
  17. Review
  18. Traditional Chinese Medicine for Pediatric Allergic Diseases.Current allergy and asthma reports · 2025
    Review
  19. Article
  20. Evolving Food Allergy Clinical Trials to Become More Patient-Centered.The journal of allergy and clinical immunology. In practice · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Suzanne M BarshowUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-6744-1834
Michael D KulisUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-8092-7444
A Wesley BurksUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-1873-5702
Edwin H KimUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-6418-1785
University of North Carolina at Chapel Hill · US

Funding

RESEARCH TRAINING IN ALLERGY AND CLINICAL IMMUNOLOGYT32AI007062 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David B. Peden, John W. Sleasman · 1985 to 2026
$6.1M
NIAID NIH HHS T32 AI007062
6 · The paper itself

Abstract

Food allergy presents a significant global health concern with up to 10% of the population affected in developed nations and a steadily increasing prevalence. In many cases, particularly with peanut, tree nut and shellfish, food allergy is a lifelong and potentially life-threatening diagnosis. While no 'cure' for IgE-mediated food allergy exists, oral immunotherapy (OIT) is a promising treatment modality with the peanut OIT drug Palforzia (Aimmune Therapeutics) the only treatment for food allergy that is currently approved by the United States Food and Drug Administration. OIT primarily induces a state of desensitization with only a minority of subjects achieving sustained unresponsiveness, a state of limited clinical remission that appears to be immunologically distinct from natural tolerance. Early humoural changes during OIT include an initial increase in allergen-specific IgE, which eventually decreases to below baseline levels as OIT progresses, and a gradual increase in allergen-specific IgA and IgG4 that continues throughout the course of OIT. Basophil hyporesponsiveness and decreased skin prick test wheal size are observed within the first year of OIT, and persistence after completion of therapy has been associated with sustained unresponsiveness. In the T-cell compartment, there is an initial expansion followed by a decline in the number and activity of T helper 2 (T

Indexed as

Administration, OralAllergensBasophilsB-LymphocytesDesensitization, ImmunologicFood HypersensitivityHumansImmunity, InnateImmunoglobulin EImmunologic MemoryMast CellsPlasma CellsTh2 CellsAllergensImmunoglobulin E

Identifiers

PMID33417257
PMCPMC9362513
OpenAlexW3118748523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.